Tru St Partnership, L.P.
Known title: 10% OwnerCIK: 0001824663
Associated companies
Transaction History
| IART | ▼ Sell | Open Market | 150,000 | $9.7M | 3/23/2022 | View on chart |
| IART | ▼ Sell | Open Market | 75,000 | $4.9M | 2/9/2022 | View on chart |
| IART | ▼ Sell | Open Market | 75,000 | $4.8M | 12/16/2021 | View on chart |
| IART | ▼ Sell | Open Market | 75,000 | $5.1M | 11/18/2021 | View on chart |
| IART | ▼ Sell | Open Market | 200,000 | $14.0M | 10/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.